A Prospective Quality of Life Study in Metastatic Pancreatic Cancer

Disease (cancer type)

Pancreatic Cancer

Contact information

  • North Florida / Jacksonville: Rhonda Calhoun (904) 427-1217

Patient Selection Criteria

• Short, non-interventional, observational, cohort, study using a mixed methods approach to explore patient-centered experience of metastatic pancreatic cancer. • Patient is receiving either Abraxane plus gemcitabine (A/G) or FOLFIRINOX (FFX) as a first line therapy for metastatic pancreatic cancer (may include modified FFX or A/G) • Patient has not been on therapy for more than one month

Research sponsor

Celgene

Reference ID#

CG1014C

State(s)

  • Florida

Linked Physicians

Back
To top